Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (231-240 of 238) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 238 results.
Basic & Clinical Pharmacology & Toxicology|May 20, 2022
First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patientsMarion Ort, Jasper Dingemanse, Chih-Hsuan Hsin, et al.
Journal of Neuropathology and Experimental Neurology|April 11, 2012
Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type CVeronika M Stein, Alexandra Crooks, Wenge Ding, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|April 11, 2017
Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studiesPaul Ratner, Charles P Andrews, Frank C Hampel, et al.
European Journal of Clinical Pharmacology|November 22, 2011
Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosisDidier Lebrec, Jaime Bosch, Rajiv Jalan, et al.
European Journal of Heart Failure|August 11, 2004
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failureGad Cotter, Edo Kaluski, Karl Stangl, et al.
Hypertension (Dallas, Tex. : 1979)|March 17, 2010
Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathyLiffert Vogt, Carlos Chiurchiu, Harbajan Chadha-Boreham, et al.
British Journal of Clinical Pharmacology|December 17, 2009
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 studyMaurice Beghetti, Sheila G Haworth, Damien Bonnet, et al.
Nature Medicine|January 30, 2007
Promotion of sleep by targeting the orexin system in rats, dogs and humansCatherine Brisbare-Roch, Jasper Dingemanse, Ralf Koberstein, et al.
Pageof 24

Showing results (231-240 of 238) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 238 results.
Basic & Clinical Pharmacology & Toxicology|May 20, 2022
First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patientsMarion Ort, Jasper Dingemanse, Chih-Hsuan Hsin, et al.
Journal of Neuropathology and Experimental Neurology|April 11, 2012
Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type CVeronika M Stein, Alexandra Crooks, Wenge Ding, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|April 11, 2017
Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studiesPaul Ratner, Charles P Andrews, Frank C Hampel, et al.
European Journal of Clinical Pharmacology|November 22, 2011
Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosisDidier Lebrec, Jaime Bosch, Rajiv Jalan, et al.
European Journal of Heart Failure|August 11, 2004
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failureGad Cotter, Edo Kaluski, Karl Stangl, et al.
Hypertension (Dallas, Tex. : 1979)|March 17, 2010
Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathyLiffert Vogt, Carlos Chiurchiu, Harbajan Chadha-Boreham, et al.
British Journal of Clinical Pharmacology|December 17, 2009
Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 studyMaurice Beghetti, Sheila G Haworth, Damien Bonnet, et al.
Nature Medicine|January 30, 2007
Promotion of sleep by targeting the orexin system in rats, dogs and humansCatherine Brisbare-Roch, Jasper Dingemanse, Ralf Koberstein, et al.
Pageof 24